The placental mesenchymal stem cells therapy is gaining popularity as a potential solution for the treatment of severe COVID-19. The Institute of Cell Therapy is acquiring recognition for successfully curing COVID-19 patients with the help of placental stem cells lacking ACE-2 receptor, which hold promising potentials in the treatment of coronavirus pneumonia. As such, worldwide inoculation of coronavirus vaccines from India has caused a slowdown in research activities of the placental stem cell therapy market.
Stakeholders in the placental stem cell therapy market are anticipated to continue their research for minimizing the impacts of future coronavirus-like outbreaks. They are boosting clinical trials to evaluate the efficacy of stem cells of different types for the treatment of COVID-19 in China.
Request a sample to get extensive insights into the Placental Stem Cell Therapy Market
The placental stem cell therapy market stood at US$ 0.5 Bn in 2019 and is expected to cross a revenue of US$ 4.4 Bn by the end of 2030. However, manufacturing is a consistent challenge for stem cell companies across various industries such as for neurological disorders, hematologic malignancies, and congenital immunodeficiency disorders. Hence, companies are mastering batch-to-batch consistency of C to monitor results.
Companies in the placental stem cell therapy market are focusing on producing cells in a consistent and quality manner. ReNeuron - a developer of therapeutics from retina specific stem cells is increasing efforts to strike the right balance between science and art to maintain consistency in cell production for the treatment of retinitis pigmentosa (RP).
To understand how our report can bring difference to your business strategy, Ask for a brochure
Mesenchymal stromal cell (MSC)-based therapies are appearing as new therapeutic strategies for lung diseases. Idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), and acute respiratory distress syndrome (ARDS), among others, have triggered the demand for mesenchymal stromal cell-based therapies. MSCs are being publicized as multipotent cells with immune modulatory and regenerative properties. This explains why the placental stem cell therapy market is estimated to progress at an astonishing CAGR of 20% during the assessment period.
The acute respiratory distress syndrome is emerging as an ideal target for the mesenchymal stromal cell-based therapy, since MSCs act as immunomodulatory cells via rapid-acting paracrine effects. Companies in the placental stem cell therapy market are increasing efforts to conduct pre-clinical studies that demonstrate the efficacy of MSCs for ARDS.
Since congenital metabolic diseases are associated with morbidity due to invasive procedures such as liver transplant, healthcare companies in the placental stem cell therapy market are capitalizing on this opportunity to offer regenerative cell therapies. Regenerative therapy using hepatocytes generated from stem cells has the potential to treat congenital metabolic diseases. This technique is gaining popularity as a less invasive cell replacement approach, suitable for the treatment of congenital metabolic diseases.
Embryonic stem cells are prone to risks of tumorigenicity and difficulties with cell expansion, owing to the number needed for the anticipated therapeutic effect. Human amniotic epithelial cells (hAECs) have caught the attention of companies in the placental stem cell therapy market to treat congenital metabolic diseases.
Cell therapy of neurological diseases is gaining momentum in the placental stem cell therapy market. Stem and progenitor cells are showing positive therapeutic results in animal models of neurological disorders within clinical trials. It has been found that each cell being tested has its advantages and drawbacks, owing to unique molecular mechanisms of action. This has led to the concept of combined transplantation of two or more cells.
The transplantation of various types of autologous or allogeneic stem/progenitor cells, including embryonic and induced pluripotent stem cells, has shown promising therapeutic outcomes in animal models of neurological diseases. Such findings are translating into revenue opportunities for companies in the placental stem cell therapy market.
Stuck in a neck-to-neck competition with other brands? Request a custom report on Placental Stem Cell Therapy Market
Analysts’ Viewpoint
Mesenchymal stem cells are emerging as powerful immunomodulators that are playing a key role in advancements made for the treatment of severe COVID-19 patients. MSC-based therapies hold future prospects for companies in the placental stem cell therapy market to create therapeutics for bronchopulmonary dysplasia (BPD) in infants born prematurely. MSCs have proven paracrine activity, which helps migrate toward inflamed sites and improves outcomes in patients suffering from neurological disorders. Ethical issues and immune mediated rejection of transplanted cells are posing as hurdles in the treatment of congenital metabolic diseases. Hence, companies should increase the production of human amniotic epithelial cells (hAECs) that are emerging as an alternative to hepatocyte transplantation (HT) for patients suffering from congenital metabolic diseases.
Placental Stem Cell Therapy Market – Segmentation
| Application |
|
| End User |
|
| Region |
|
Placental stem cell therapy market is expected to cross a revenue of US$ 4.4 Bn by the end of 2030
Placental stem cell therapy market is projected to expand at a CAGR of 20% from 2020 to 2030
Placental stem cell therapy market is driven by increase in awareness about stem cell therapies
The neurological disorders segment held a significant share of the global placental stem cell therapy market
Key players operating in the global placental stem cell therapy market include Lifebank Stem Cell Banking, Celularity, Inc., Americord Registry, ReeLabs Pvt. Ltd., Pluristem Therapeutics, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Placental Stem Cell Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Application Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Placental Stem Cell Therapy Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Supply Chain Analysis
5.1.1. Placental Stem Cells Collection & Isolation
5.1.2. Cell processing & Cryo-preservation
5.1.3. Cell Differentiation
5.1.4. Cell Culture and Expansion
5.2. Pipeline Analysis
5.3. Regulatory Scenario, by Region/globally
5.4. Reimbursement Scenario, by Region/globally
5.5. Pricing Analysis, 2019
5.6. COVID-19 Pandemic Impact on Industry
6. Global Placental Stem Cell Therapy Market Analysis and Forecast, by Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030
6.3.1. Hematologic Malignancies and Disorders
6.3.2. Congenital Immunodeficiency Disorders
6.3.3. Metabolic Disorders
6.3.4. Neurological Disorders
6.3.5. Others
6.4. Global Placental Stem Cell Therapy Market Attractiveness Analysis, by Application
7. Global Placental Stem Cell Therapy Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030
7.3.1. Hospitals & Specialty Clinics
7.3.2. Clinical Research Organizations
7.3.3. Research Institutes & Academies
7.4. Global Placental Stem Cell Therapy Market Attractiveness Analysis, by End-user
8. Global Placental Stem Cell Therapy Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Placental Stem Cell Therapy Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Placental Stem Cell Therapy Market Attractiveness Analysis, by Country/Region
9. North America Placental Stem Cell Therapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030
9.2.1. Hematologic Malignancies and Disorders
9.2.2. Congenital Immunodeficiency Disorders
9.2.3. Metabolic Disorders
9.2.4. Neurological Disorders
9.2.5. Others
9.3. North America Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030
9.3.1. Hospitals & Specialty Clinics
9.3.2. Clinical Research Organizations
9.3.3. Research Institutes & Academies
9.4. North America Placental Stem Cell Therapy Market Value Forecast, by Country, 2018–2030
9.4.1. U.S.
9.4.2. Canada
9.5. North America Placental Stem Cell Therapy Market Attractiveness Analysis
9.5.1. By Application
9.5.2. By End-user
9.5.3. By Country
10. Europe Placental Stem Cell Therapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030
10.2.1. Hematologic Malignancies and Disorders
10.2.2. Congenital Immunodeficiency Disorders
10.2.3. Metabolic Disorders
10.2.4. Neurological Disorders
10.2.5. Others
10.3. Europe Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030
10.3.1. Hospitals & Specialty Clinics
10.3.2. Clinical Research Organizations
10.3.3. Research Institutes & Academies
10.4. Europe Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Placental Stem Cell Therapy Market Attractiveness Analysis
10.5.1. By Application
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Placental Stem Cell Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030
11.2.1. Hematologic Malignancies and Disorders
11.2.2. Congenital Immunodeficiency Disorders
11.2.3. Metabolic Disorders
11.2.4. Neurological Disorders
11.2.5. Others
11.3. Asia Pacific Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030
11.3.1. Hospitals & Specialty Clinics
11.3.2. Clinical Research Organizations
11.3.3. Research Institutes & Academies
11.4. Asia Pacific Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Placental Stem Cell Therapy Market Attractiveness Analysis
11.5.1. By Application
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Placental Stem Cell Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030
12.2.1. Hematologic Malignancies and Disorders
12.2.2. Congenital Immunodeficiency Disorders
12.2.3. Metabolic Disorders
12.2.4. Neurological Disorders
12.2.5. Others
12.3. Latin America Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030
12.3.1. Hospitals & Specialty Clinics
12.3.2. Clinical Research Organizations
12.3.3. Research Institutes & Academies
12.4. Latin America Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Placental Stem Cell Therapy Market Attractiveness Analysis
12.5.1. By Application
12.5.2. By End-user
12.5.3. By Country//Sub-region
13. Middle East & Africa Placental Stem Cell Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Placental Stem Cell Therapy Market Value Forecast, by Application, 2018–2030
13.2.1. Hematologic Malignancies and Disorders
13.2.2. Congenital Immunodeficiency Disorders
13.2.3. Metabolic Disorders
13.2.4. Neurological Disorders
13.2.5. Others
13.3. Middle East & Africa Placental Stem Cell Therapy Market Value Forecast, by End-user, 2018–2030
13.3.1. Hospitals & Specialty Clinics
13.3.2. Clinical Research Organizations
13.3.3. Research Institutes & Academies
13.4. Middle East & Africa Placental Stem Cell Therapy Market Value Forecast, by Country/Sub-region, 2018–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Placental Stem Cell Therapy Market Attractiveness Analysis
13.5.1. By Application
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2019
14.3. Company Profiles
14.3.1. Lifebank Stem Cell Banking
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Celularity, Inc.
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Americord Registry
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. ReeLabs Pvt. Ltd.
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Pluristem Therapeutics, Inc.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Mesoblast Limited
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. ReNeuron Group plc
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Athersys, Inc.
14.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview
14.3.9. Other Prominent Key Players
List of Tables
Table 1: Global Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Application, 2018–2030
Table 2: Global Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 3: Global Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 4: North America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 5: North America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Application, 2018–2030
Table 6: North America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 7: Europe Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 8: Europe Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Application, 2018–2030
Table 9: Europe Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 10: Asia Pacific Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 11: Asia Pacific Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Application, 2018–2030
Table 12: Asia Pacific Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 13: Latin America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 14: Latin America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Application, 2018–2030
Table 15: Latin America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2018–2030
Table 16: Middle East & Africa Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 17: Middle East & Africa Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by Application, 2018–2030
Table 18: Middle East & Africa Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2018–2030
List of Figures
Figure 1: Global Placental Stem Cell Therapy Market Value (US$ Mn) Forecast, 2018–2030
Figure 2: Global Placental Stem Cell Therapy Market Value Share, by Application (2019)
Figure 3: Global Placental Stem Cell Therapy Market Value Share, by End-user (2019)
Figure 4: Global Placental Stem Cell Therapy Market Value Share, by Region (2019)
Figure 5: Global Placental Stem Cell Therapy Market Value Share Analysis, by Application, 2019 and 2030
Figure 6: Global Placental Stem Cell Therapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 7: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Hematologic Malignancies and Disorders, 2018–2030
Figure 8: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Congenital Immunodeficiency Disorders, 2018–2030
Figure 9: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Metabolic Disorders, 2018–2030
Figure 10: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Neurological Disorders, 2018–2030
Figure 11: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Others, 2018–2030
Figure 12: Global Placental Stem Cell Therapy Market Value Share Analysis, by End-user, 2019 and 2030
Figure 13: Global Placental Stem Cell Therapy Market attractiveness index Analysis, by End-user, 2020–2030
Figure 14: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Hospitals & Specialty Clinics, 2018–2030
Figure 15: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Clinical Research Organizations, 2018–2030
Figure 16: Global Placental Stem Cell Therapy Market Value (US$ Mn), by Research Institutes & Academies, 2018–2030
Figure 17: Global Placental Stem Cell Therapy Market Value Share Analysis, by Region, 2019 and 2030
Figure 18: Global Placental Stem Cell Therapy Market Attractiveness Analysis, by Region, 2020–2030
Figure 19: North America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 20: North America Placental Stem Cell Therapy Market Value Share, by Country, 2019–2030
Figure 21: North America Placental Stem Cell Therapy Market Attractiveness, by Country, 2019–2030
Figure 22: North America Placental Stem Cell Therapy Market Value Share (%), by Application, 2019 and 2030
Figure 23: North America Placental Stem Cell Therapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 24: North America Placental Stem Cell Therapy Market Value Share (%), by End-user, 2019 and 2030
Figure 25: North America Placental Stem Cell Therapy Market Attractiveness Analysis, by End-user, 2020–2030
Figure 26: Europe Placental Stem Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 27: Europe Placental Stem Cell Therapy Market Value Share, by Country, 2019–2030
Figure 28: Europe Placental Stem Cell Therapy Market Attractiveness, by Country, 2019–2030
Figure 29: Europe Placental Stem Cell Therapy Market Value Share (%), by Application, 2019 and 2030
Figure 30: Europe Placental Stem Cell Therapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 31: Europe Placental Stem Cell Therapy Market Value Share (%), by End-user, 2019 and 2030
Figure 32: Europe Placental Stem Cell Therapy Market Attractiveness Analysis, by End-user, 2020–2030
Figure 33: Asia Pacific Placental Stem Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 34: Asia Pacific Placental Stem Cell Therapy Market Value Share, by Country, 2019–2030
Figure 35: Asia Pacific Placental Stem Cell Therapy Market Attractiveness, by Country, 2019–2030
Figure 36: Asia Pacific Placental Stem Cell Therapy Market Value Share (%), by Application, 2019 and 2030
Figure 37: Asia Pacific Placental Stem Cell Therapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 38: Asia Pacific Placental Stem Cell Therapy Market Value Share (%), by End-user, 2019 and 2030
Figure 39: Asia Pacific Placental Stem Cell Therapy Market Attractiveness Analysis, by End-user, 2020–2030
Figure 40: Latin America Placental Stem Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 41: Latin America Placental Stem Cell Therapy Market Value Share, by Country, 2019–2030
Figure 42: Latin America Placental Stem Cell Therapy Market Attractiveness, by Country, 2019–2030
Figure 43: Latin America Placental Stem Cell Therapy Market Value Share (%), by Application, 2019 and 2030
Figure 44: Latin America Placental Stem Cell Therapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 45: Latin America Placental Stem Cell Therapy Market Value Share (%), by End-user, 2019 and 2030
Figure 46: Latin America Placental Stem Cell Therapy Market Attractiveness Analysis, by End-user, 2020–2030
Figure 47: Middle East Africa Placental Stem Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 48: Middle East Africa Placental Stem Cell Therapy Market Value Share, by Country, 2019–2030
Figure 49: Middle East Africa Placental Stem Cell Therapy Market Attractiveness, by Country, 2019–2030
Figure 50: Middle East Africa Placental Stem Cell Therapy Market Value Share (%), by Application, 2019 and 2030
Figure 51: Middle East Africa Placental Stem Cell Therapy Market Attractiveness Analysis, by Application, 2020–2030
Figure 52: Middle East Africa Placental Stem Cell Therapy Market Value Share (%), by End-user, 2019 and 2030
Figure 53: Middle East Africa Placental Stem Cell Therapy Market Attractiveness Analysis, by End-user, 2020–2030
Figure 54: Market Position Analysis, 2018, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Placental Stem Cell Therapy Market
*86 figures and 60 tables includes